8-K - TELA Bio, Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

TELA Bio, Inc. received a deficiency letter from Nasdaq on March 17, 2026, notifying that its common stock's closing bid price was below $1.00 per share for 30 consecutive business days, violating Nasdaq Listing Rule 5450(a)(1). The Company has 180 calendar days until September 14, 2026, to regain compliance by achieving $1.00+ closes for 10 consecutive business days, with no immediate effect on its Nasdaq Global Market listing.

Key Takeaways

1Received Nasdaq deficiency letter on March 17, 2026

2Closing bid price below $1.00 for 30 consecutive business days prior to notice

3180 calendar days to comply, ending September 14, 2026

4Compliance via $1.00+ bid price for 10 consecutive business days

5Possible second 180-day period if transfers to Nasdaq Capital Market

6Stock continues trading on Nasdaq Global Market under symbol TELA

Current Report Details

Event Type

Delisting

Disclosure

Mandatory

Variant

8-K

Items Reported

3.01

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On March 17, 2026, TELA Bio, Inc. (the “ Company ”) receive

Delisting

$1.00$1.00

Exhibits (1)

8-K

FORM 8-K